CA2395429A1 - Vaccins polynucleotidiques exprimant le gene pol du vih-1 a optimisation des codons et le gene pol du vih-1 modifie - Google Patents

Vaccins polynucleotidiques exprimant le gene pol du vih-1 a optimisation des codons et le gene pol du vih-1 modifie Download PDF

Info

Publication number
CA2395429A1
CA2395429A1 CA002395429A CA2395429A CA2395429A1 CA 2395429 A1 CA2395429 A1 CA 2395429A1 CA 002395429 A CA002395429 A CA 002395429A CA 2395429 A CA2395429 A CA 2395429A CA 2395429 A1 CA2395429 A1 CA 2395429A1
Authority
CA
Canada
Prior art keywords
pol
dna
hiv
lys
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002395429A
Other languages
English (en)
Inventor
John W. Shiver
Helen C. Perry
Danilo R. Casimiro
Tong-Ming Fu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2395429A1 publication Critical patent/CA2395429A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à des compositions pharmaceutiques comportant des vaccins à base d'ADN du gène Pol du VIH, ainsi qu'à la production et à l'utilisation de ces vaccins à base d'ADN. Ces vaccins d'ADN à base du gène pol sont administrés par introduction directe dans le tissu de vertébrés vivants, de préférence des humains, et ils expriment de préférence des régions inactivées de la protéine Pol du VIH exempte d'activité de protéase, de transcriptase inverse, de Rnase H et d'intégrase, induisant ainsi une réponse immunitaire cellulaire qui reconnaît spécifiquement le virus-1 de l'immunodéficience humaine (HIV-1). Les molécules d'ADN qui comportent la phase ouverte de lecture de ces vaccins d'ADN sont des molécules d'ADN synthétiques codant pour le gène Pol du HIV-1 à optimisation des codons et des dérivés inactifs à optimisation des codons du gène Pol du HIV-1 optimisé, et notamment des molécules qui codent des protéines Pol inactives comportant un signal peptidique N-terminal.
CA002395429A 1999-12-22 2000-12-21 Vaccins polynucleotidiques exprimant le gene pol du vih-1 a optimisation des codons et le gene pol du vih-1 modifie Abandoned CA2395429A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17154299P 1999-12-22 1999-12-22
US60/171,542 1999-12-22
PCT/US2000/034724 WO2001045748A1 (fr) 1999-12-22 2000-12-21 Vaccins polynucleotidiques exprimant le gene pol du vih-1 a optimisation des codons et le gene pol du vih-1 modifie

Publications (1)

Publication Number Publication Date
CA2395429A1 true CA2395429A1 (fr) 2001-06-28

Family

ID=22624133

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002395429A Abandoned CA2395429A1 (fr) 1999-12-22 2000-12-21 Vaccins polynucleotidiques exprimant le gene pol du vih-1 a optimisation des codons et le gene pol du vih-1 modifie

Country Status (5)

Country Link
EP (1) EP1242124A4 (fr)
JP (1) JP2003520786A (fr)
AU (1) AU779951B2 (fr)
CA (1) CA2395429A1 (fr)
WO (1) WO2001045748A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2001002607A1 (fr) 1999-07-06 2001-01-11 Merck & Co., Inc. Vaccin contre le vih comprenant un adenovirus vehiculant le gene gag
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU9456201A (en) * 2000-09-15 2002-03-26 Merck & Co Inc Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
AU2002316578A1 (en) * 2001-08-31 2003-03-18 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
EP2185195A2 (fr) 2007-08-16 2010-05-19 Tripep Ab Plate-forme immunogène
IT201900016718A1 (it) 2019-09-19 2021-03-19 Takis S R L Combinazione di agenti immunomodulatori con neoantigeni tumore-specifici per l’uso nella prevenzione e nel trattamento dei tumori.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010230A1 (fr) * 1989-02-23 1990-09-07 University Of Ottawa Polypeptide avec activite immunologique destine a servir de vaccin et/ou de reactif diagnostique
US5851813A (en) * 1990-07-12 1998-12-22 President And Fellows Of Harvard College Primate lentivirus antigenic compositions
ATE309366T1 (de) * 1996-02-22 2005-11-15 Merck & Co Inc Synthetische hiv-gene
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use

Also Published As

Publication number Publication date
AU2585801A (en) 2001-07-03
EP1242124A4 (fr) 2004-07-14
EP1242124A1 (fr) 2002-09-25
AU779951B2 (en) 2005-02-24
JP2003520786A (ja) 2003-07-08
WO2001045748A1 (fr) 2001-06-28

Similar Documents

Publication Publication Date Title
KR101501495B1 (ko) Ｈｉｖ-감염의 예방 및 치료를 위한 백신
US8323961B2 (en) HIV vaccines based on adenoviral vectors encoding Env from multiple clades of HIV
Cease et al. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.
JP4805511B2 (ja) Ｈｉｖに対する免疫応答における改善、または免疫応答に関する改善
CA2258568A1 (fr) Vaccins comprenant des genes de synthese
PL211762B1 (pl) Zastosowanie białka fuzyjnego zawierającego białka HIV Tat i HIV Nef lub polinukleotyd kodujący takie białko, białka lub polinukleotydu HIV gp120, białka lub polinukleotydu SIV Nef, adiuwanta indukującego TH1 zawierającego monofosforylolipid A lub jego pochodną i adiuwanta saponinowego oraz kompozycja szczepionki
US20040191269A1 (en) Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
KR19990087126A (ko) 합성 사람 면역결핍 바이러스 유전자
KR20100109555A (ko) 백신
AU2005274059A1 (en) Adenoviral vector compositions
US20050215508A1 (en) Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
JP2005507377A (ja) ＨＩＶに対する免疫のためのｇｐ１２０と、Ｎｅｆ及び／又はＴａｔを含むワクチン
AU782193B2 (en) Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
CA2395429A1 (fr) Vaccins polynucleotidiques exprimant le gene pol du vih-1 a optimisation des codons et le gene pol du vih-1 modifie
KR20230087583A (ko) 항원을 mhc-ii 경로로 전달하고 숙주에서 cd4+ 및 cd8+ t-세포 반응을 유도하는 새로운 세대의 렌티바이러스 벡터
US20060148750A1 (en) Polynucleotide vaccines expressing codon optimized HIV-1 Pol and modified HIV-1 Pol
Achour et al. Induction of anti-gp160 cytotoxic T cells cross-reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope-immunized individuals
CA2943603A1 (fr) Sequences du vih -1 en mosaique et utilisations de celles-ci
Human et al. Progress in Gene Therapy: Basic and Clinical Frontiers, pp. 361-386 R. Bertolotti et al.(Eds)© VSP 2000
CA2245646A1 (fr) Genes synthetiques du vih

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead